Dr Reddy’s Lab inks licensing pact with US-based Slayback Pharma


The company has inked a licensing pact with the NewJersey-based drug firm to acquire rights in Brimonidine Tartrate Ophthalmic Solution 0.025 percent, the Hyderabad-based firm said in a statement.

As per industry estimates, the value of the total addressable market for this product in the US is around USD 130 million for the 52 weeks ending June 12, 2022. Pic: https://www.drreddys.com/

Leave a Reply

Your email address will not be published. Required fields are marked *